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Commercial kitReal-time polymerase chain reaction (PCR) can be considered the gold standard for detection of inﬂuenza
viruses due to its high sensitivity and speciﬁcity. Roche has developed the RealTime ready Inﬂuenza A/H1N1
Detection Set, consisting of a generic inﬂuenza virus A PCR targeting the M2 gene (M2 PCR) and a speciﬁc PCR
targeting the hemagglutinin (HA) of A/H1N1-pdm09 (HA PCR, 2009 H1N1), with the intention to make a
reliable, rapid, and simple test to detect and quantify 2009 H1N1 in clinical samples. We evaluated this kit
against the US Centers for Disease Control and Prevention (USCDC)/World Health Organization real-time PCR
for inﬂuenza virus using 419 nose and throat swabs from 210 patients collected in 3 large hospitals in Ho Chi
Minh City, Vietnam. In the per-patient analysis, when compared to CDC PCR, the sensitivity and speciﬁcity of
the M2 PCRwere 85.8% and 97.6%, respectively; the sensitivity and speciﬁcity of HA PCRwere 88.2% and 100%,
respectively. In the per-sample analysis, the sensitivity and speciﬁcity in nose swabs were higher than those in
throat swabs for both M2 and HA PCRs. The viral loads as determined with the M2 and HA PCRs correlated
well with the Ct values of the CDC PCR. Compared with the CDC PCR, the kit has a reasonable sensitivity and
very good speciﬁcity for the detection and quantiﬁcation of inﬂuenza A virus and A/H1N1-pdm09. However,
given the current status of 2009 H1N1, a kit that can detect all circulating seasonal inﬂuenza viruses would
be preferable.East Asian Infectious diseases
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On April 17, 2009, the US Centers for Disease Control and
Prevention (USCDC) conﬁrmed 2 cases of respiratory illness from
Mexico and the United States that were caused by infection with a
novel inﬂuenza virus A: A/H1N1-pdm09 (2009 H1N1) (CDC, 2009a,
2009b). In late April, the World Health Organization (WHO)announced the local spread in North America of 2009 H1N1, and by
June 11, 2009, with sustained transmission occurring in 2 continents
and across 2WHO regions, theWHO declared that the infectionwas in
phase 6 of the pandemic inﬂuenza phases (Chan, 2009). Although the
infection spread rapidly around the world, the majority of cases were
mild, although the risk factors for severe illness differed from seasonal
inﬂuenza with a higher incidence of severe disease among pregnant
women, obese individuals, and young adults (Carcione et al., 2010;
Donaldson et al., 2009; Dubar et al., 2010; ECDC, 2009; Lim et al.,
2010; Muscatello et al., 2010). In the post-pandemic period, 2009
H1N1 has replaced the previously circulating H1N1 virus as the
dominant seasonal inﬂuenza viral strain (WHO, 2011).
The laboratory has a vital role in detecting and subtyping novel
inﬂuenza viruses. Laboratory diagnosis facilitates treatment and
surveillance, and reduces health care costs (Petric et al., 2006).
Rapid test kits were used for detecting 2009 H1N1, but these had low
sensitivity (Choi et al., 2010; Kwon et al., 2011; Stevenson and
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also suffered from low sensitivity and could only be used to diagnose
2009 H1N1 retrospectively (Veguilla et al., 2011). Reverse transcrip-
tion–polymerase chain reaction (RT-PCR) is a reliable diagnostic
approach with high sensitivity and speciﬁcity and rapid time to result
when compared to virus culture (Petric et al., 2006).
The USCDC designed and optimized protocols for real-time RT-PCR
(rRT-PCR) for seasonal and avian inﬂuenza A and B viruses (version
2007) and 2009 H1N1 (version 2009) (US Department of Health and
Human Services, 2008; Chan, 2009). This PCR (CDC PCR) was an
effective diagnostic assay for the rapid detection of 2009 H1N1 in
clinical samples (Shu et al., 2011). In addition, a large number of RT-
PCR assays for 2009 H1N1 were developed and used as in-house
assays with a high sensitivity. (Binsaeed et al., 2011; Chidlow et al.,
2010; Ellis et al., 2009; He et al., 2009; Huber et al., 2011; Lee et al.,
2010; Nakauchi et al., 2011; Pabbaraju et al., 2009; Poon et al., 2009;
Schulze et al., 2010; Selvaraju and Selvarangan, 2010; Shin et al.,
2011; Wenzel et al., 2009; Wenzel et al., 2010; Whiley et al., 2009).
In this study, we compared the performance of a novel Roche
RealTime Ready Inﬂuenza A/H1N1 Detection Set (Roche Diagnostics,
Mannheim, Germany) with the CDC PCR for detecting 2009 H1N1 and
other inﬂuenza A viruses in clinical specimens from Vietnam.2. Materials and methods
2.1. Study sites, patient population, and sample size
Patients with an inﬂuenza-like illness and a positive CDC PCR were
asked to participate in a double-blind randomized controlled trial of
standard versus double-dose oseltamivir in severe inﬂuenza
(NCT00298233) and when that trial was completed a descriptive
study of oseltamivir treatment of 2009 H1N1 (NCT00985582). These
studies will be reported elsewhere, but, brieﬂy, severe illness was
deﬁned as one of the following: new inﬁltrate on chest X-ray; severe
tachypnea (respiratory rate ≥30 for ages ≥12 years); severe dyspnea
(unable to speak full sentences or use accessory respiratory muscles);
arterial oxygen saturation ≤92% on room air by transcutaneous
method; and requiring mechanical ventilation at presentation.
Patients were excluded from enrollment if they had received more
than 72 h of oseltamivir (6 doses) or received oseltamivir at higher
than standard doses within the last 14 days. In NCT00985582, patients
aged over 1 month with virologically conﬁrmed 2009 H1N1 inﬂuenza
were enrolled into a single-arm clinical, virologic, and pharmacologic
study to assess the use of oral oseltamivir. Mild inﬂuenza was deﬁned
as fever within the past 7 days plus any 2 of cough, myalgia, lethargy,
sore throat, or runny nose.
Two specimens (1 nose swab and 1 throat swab) were collected in
separate tubes containing 3 mL of Remel M4 transport medium
(Remel, Lenexa, KS, USA) from each subject on the day of enrolment
and stored at −80 °C until used. Samples from 210 patients were
randomly selected for this study. From the initial screening results, it
was known that these patients were infected with 1977 H1N1 (n =
24), H3N2 (n = 27), H5N1 (n = 1), inﬂuenza B (n = 23), and 2009
H1N1 (n = 135). Nose and throat swabs taken on the day of study
enrolment (different samples from the initial screening samples)
were used for this study and retested with the Roche rRT-PCR.2.2. Nucleic acid extraction
Total nucleic acids were extracted from 100 μL of clinical specimen
and eluted in 60 μL of elution buffer using the automated easyMAG
system (bioMérieux, Marcy l'Étoile, France), according to the
manufacturer's instructions. Nucleic acid was used immediately
(CDC PCR) or stored at −80 °C until used (Roche rRT-PCR).2.3. RealTime ready Inﬂuenza A/H1N1 Detection Set (Roche rRT-PCR)
Detection of inﬂuenza virus A is based on the conserved matrix
protein 2 (M2) of 2009 H1N1 on a variable part of the hemagglutinin
(HA). The primer/probe sets used have been described previously
(Panning et al., 2009; Ward et al., 2004). These assays also received
emergency-use authorization from the Food and Drug Administration.
The detection set includes the described primer probe set, external
and internal PCR controls, a detection set for human nucleic acids as
internal sample control, and molecular grade water. RT-PCR was done
according to the instructions of the manufacturer. For ampliﬁcation,
5 μL of extracted nucleic acids was added to each reaction mix (M2
and HA) and thermal cycling was performed in a LightCycler 480 II
instrument (Roche Diagnostics, Mannheim, Germany) using the
following conditions for both PCRs: 50 °C for 8 min (reverse-
transcriptase step), 95 °C for 30 s, followed by 45 cycles of 95 °C for
1 s, 60 °C for 20 s, 72 °C for 1 s, and cooling to 40 °C for 30 s. Results
were interpreted as positive if the crossing point (Cp) value was ≤40
and as negative if no value or Cp value was N40.
2.4. Reference testing
rRT-PCR for detection of inﬂuenza A and B viruses was done
according to WHO/USCDC protocols (CDC Real-time RT PCR Protocol
for Detection and Characterization of Inﬂuenza [version 2007 and
2009]) using Superscript III One-step RT-PCR with Platinum Taq
(Invitrogen, Carlsbad, CA, USA) on a DNA Engine Peltier Thermocycler
platform with a Chromo4 RT PCR detector (Bio-Rad, Hercules, CA,
USA). Brieﬂy, 2 × 5 μL of extracted nucleic acids were added to the
reaction mix for detection of inﬂuenza virus A and B and an additional
6 reactions were performed using 5 μL per reaction for further
subtyping of the HA of inﬂuenza virus A (1977 H1N1, 2009 H1N1 [2:
HA and swine inﬂuenza speciﬁc NP], H3N2, and H5N1 [2]). An
external sample control targeting human RNase P was performed on
each specimen. Only specimens with a cycle threshold (Ct) value of 35
or lower were considered of acceptable quality. Inﬂuenza virus A was
detected with oligonucleotides targeting the M protein and 2009
H1N1 was subsequently subtyped using oligonucleotides targeting
the NP of swine-origin H1 virus and the HA of 2009 H1N1. The results
of the M and HA PCRs were compared.
2.5. Data analysis
Performance of the kit was evaluated as the sensitivity and
speciﬁcity of the test in comparison to CDC PCR. Results were
analyzed using R version 2.11.1 (Foundation for Statistical Computing,
Vienna, Austria).
2.6. Ethics
The trial protocols (SEA001 and SEA032) were approved by the
ethics committee of each institution, the National Institute of Allergy
and Infectious Diseases (NIAID) Institutional Review Board, and the
Oxford Tropical Research Ethics Committee, and were conducted in
accordance with Good Clinical Practice. The trials were registered at
clinicaltrials.gov as NCT00298233 and NCT00985582.
3. Results
Samples from 210 virologically conﬁrmed inﬂuenza patients were
used. The median age of the patients was 16.8 years (range 1–
78 years; interquartile range 2.1–25.8 years), with a female/male ratio
of 0.49 (102):0.51 (108). Samples taken on the day of study
enrolment were used; on study enrolment, 169 patients were positive
for inﬂuenza A viruses (twenty-three 1977 H1N1, twenty-six H3N2,
one H5N1, and one hundred nineteen 2009 H1N1) and 19 for
Table 1
Results of Roche rRT-PCR A/M2 and A/H1N1 assays compared to CDC rRT-PCR for the detection of inﬂuenza virus (M2) and inﬂuenza virus A/H1N1-pdm09 (H1); per-patient and
per-sample (nose and throat swab) analysis.
CDC rRT-PCR kappa value Sensitivity, %(95% CI) Speciﬁcity, %(95% CI) PPV (%) NPV (%)
Positive Negative
M2 per patient
Positive 145 1 0.69 85.8 (79.6–90.7) 97.6 (87.1–99.9) 99.3 62.5
Negative 24 40
Total 169 41
H1 per patient
Positive 105 0 0.87 88.2 (91.0–93.4) 100 (96.0–100) 100 86.7
Negative 14 91
Total 119 91
M2 per nose swab
Positive 126 1 0.75 84.6 (77.7–90.0) 98.3 (91.0–100) 99.2 72
Negative 23 59
Total 149 60
H1 per nose swab
Positive 90 0 0.88 87.4 (79.4–93.1) 100 (96.6–100) 100 89.1
Negative 13 106
Total 103 106
M2 per throat swab
Positive 91 3 0.49 63.2 (54.8–71.1) 95.5 (87.3–99.1) 96.8 54.3
Negative 53 63
Total 144 66
H1 per throat swab
Positive 77 1 0.77 77.0 (67.5–84.8) 99.1 (95.0–100) 98.7 82.6
Negative 23 109
Total 100 110
CI = Conﬁdence interval; PPV = positive predictive value; NPV = negative predictive value.
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All external sample controls in CDC PCR were positive (sufﬁcient
amount of human cell material), and all internal controls in Roche PCR
were positive (no inhibition of RT-PCR reactions).
3.1. Per-patient analysis
A patient was considered positive when the nose swab or the
throat swab (or both) was positive. Patients were considered negative
when both nose and throat swab were negative or when 1 swab was
negative and the other was not done.
Among 169 patients positive for inﬂuenza A in the CDC PCR, 145
were positive in the M2 PCR (sensitivity 85.8%). Among 41 negative
patients, 40 were negative in the M2 PCR and 1 patient was positive
(nose swab negative; throat swab Cp value 39.84). Among 119
patients positive for 2009 H1N1, 105 were also positive in the HA PCR
(sensitivity 88.2%). All 91 negative patients were also negative with
the Roche HA PCR. No cross-reactivity was observed in any of these
210 patients, between inﬂuenza A and B (M2 PCR) or in subtyping
seasonal inﬂuenza A and pandemic H1N1 (HA PCR) (Table 1).
3.2. Per-sample analysis
A total of 419 stored RNA samples (209 nose swabs and 210 throat
swabs) were tested with both the M2 and the HA assay from the
Roche kit (1 nose swab had insufﬁcient volume).
Among 209 nose swabs, 149 were positive for inﬂuenza A in CDC
PCR, and 126 of those were positive when tested with the M2 PCR
(sensitivity 84.6%). Fifty-nine of 60 CDC PCR negative were also
negative in the M2 PCR. Of 103 positive swabs for 2009 H1N1 in CDC
PCR, 90 were positive in the HA PCR (sensitivity 87.4%). All swabs
that were negative in CDC PCR were also negative in the HA PCR (106/
106) (Table 1).
Among 210 throat swabs were tested, the M2 PCR identiﬁed 91 of
144 CDC PCR positive for inﬂuenza A virus infection (sensitivity
63.2%). Of 66 negative swabs, 63were negative and 3were positive for
M2 PCR (Cp value in M2 PCR: 32.66, 39.08, and 39.84; in HA PCR:29.72, negative, and negative, respectively). One hundred throat
swabs were positive in CDC PCR; 77 of those were positive HA PCR
(sensitivity 77.0%). Among 110 swabs which tested negative in CDC
PCR, 109 were also negative in the A/H1N1 assay and 1 swab was
positive (Cp value 29.72) (Table 1).
3.3. Correlation between CDC PCR and M2 and HA PCRs
Among samples with lower Ct values in the CDC PCR, the positivity
rates for the Roche M2 and HA PCRs in both nose and throat swabs
were higher: the mean Ct values of samples that were only positive in
CDC PCR were higher than those of samples that were positive in both
CDC PCR and Roche rRT-PCRs in nose and throat swabs (Fig. 1).
The correlation between Ct values in CDC PCR and Cp values in M2
and HA PCR was high for both specimens: 0.85 and 0.91 in nose
swabs; 0.81 and 0.82 in throat swabs, respectively.
The log10 of the amount of viral genome copies in nose and throat
swabs determined in a quantitative PCR is inversely proportional to
the Ct values. Correlation between Ct values of the CDC PCR and the
log10 of the amount of viral genome copies in the Roche M2 and HA
PCRs was assessed. The correlation betweenM2 PCR and CDC PCRwas
−0.83 and −0.81; between HA PCR and CDC PCR was −0.93 and −
0.83 in nose swabs and throat swabs, respectively (Fig. 2).
4. Discussion
Although virus culture is still considered the gold standard for
inﬂuenza diagnostics, including 2009 H1N1, numerous publications
have shown real-time PCR to have a higher sensitivity and shorter
turnaround time and this technique can therefore be considered a
surrogate gold standard (Petric et al., 2006). Several assays (including
duplex and multiplex assays) were designed and validated with high
sensitivity (range 83–100%) and used as diagnostic assays to detect
2009 H1N1 routinely or for surveillance of inﬂuenza activity (Chidlow
et al., 2010; Ellis et al., 2009; He et al., 2009; Huber et al., 2011; Lee
et al., 2010; Nakauchi et al., 2011; Pabbaraju et al., 2009; Poon et al.,
Fig. 1. Relatedness of results of CDC rRT-PCR and Roche rRT-PCR A/M2 and A/H1N1 assays in nose (A) and throat swabs (B). The x-axis represents the Ct value in CDC rRT-PCR for
each specimen. Closed circles represent specimens with a positive Roche rRT-PCR A/H1N1 assay result; closed triangles, specimens with a positive Roche rRT-PCR A/M2 assay result.
Open circles and triangles indicate specimens with a negative result for the respective assays. The vertical line is the mean Ct value in CDC rRT-PCR in each group.
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et al., 2011; Wenzel et al., 2009; Whiley et al., 2009).
We conducted a study to evaluate the novel Roche RealTime ready
Inﬂuenza A/H1N1 Detection Set, consisting of a generic M2 and a
speciﬁc HA PCR, on a large number (419) of swabs from patients who
tested positive for inﬂuenza A or B virus on screening for enrolment
into oseltamivir treatment trials in comparison with the CDC PCR as
gold standard. The sensitivity of the M2 PCR (range 63.2–85.8%) and
the HA PCR (range 77.0–88.2%) was lower than that of previously
published assays.
The performance of the M2 and HA assays of the detection kit
was assessed and validated before (Ward et al., 2004), showing that
the limit of detection of the assays was under 50 RNA copies per
reaction of PCR. Furthermore, a high positive agreement between
M2 assay and CDC PCR (99%), and between HA assay and CDC PCR(98%) was attained when performed on clinical samples with 88%
negative agreement.
In our study, we tested a larger number of positive clinical samples
(both seasonal inﬂuenza and pandemic H1N1 inﬂuenza virus) than in
the previous testing.
Positive agreement of these assays and CDC PCR was slightly lower
(both per-patient and per-sample analysis) (range 63.0–88.2%), and
negative agreement was higher (range 95.5–100%). The agreement
between CDC PCR andM2 PCRwasmedium in throat swabs (κ=0.49),
but good in nose swabs and in per-patient analysis (κ= 0.75 and 0.69,
respectively). The agreement between CDC PCR and HA PCR was from
good (in throat swabs, κ= 0.77) to very good (in nose swabs and per-
patient analysis, κ = 0.88 and 0.87, respectively).
The kit has the additional beneﬁt of quantiﬁcation of viral loads.
Although the CDC PCR is not set up quantitatively, there was a strong
Fig. 2. Correlation of Ct value in CDC rRT-PCR and log10 viral genome copies per milliliter of viral transport medium in Roche rRT-PCR A/M2 assays in positive nose (A) and throat (B)
swabs and in Roche rRT-PCR A/H1 assays in nose (C) and throat (D) swabs.
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log10 viral loads of samples in M2 and HA PCRs.
The kit, including extraction, takes 2 h for both HA PCR andM2 PCR,
which is shorter than the CDC PCR (2.5 h). The Roche detection kit is
convenient, easy to use, and requires a minimum of expertise. When
assessing performance to detect 2009 H1N1, the HA PCR is more
sensitive and more speciﬁc than the M2 PCR. The Roche kit is intended
for use in nose swabs, nasopharyngeal swabs, nasal washes, or nasal
aspirates. Indeed, nose swabs were more often positive and at lower Ct
values (higher viral loads) than throat swabs; as has been published
before (Ngaosuwankul et al., 2010). The kit does not subtype seasonal
inﬂuenza A viruses nor does it detect inﬂuenza virus B. Ideally, a kit to
diagnose inﬂuenza viruses should include H3N2 and ﬂu B–speciﬁc
primers, especially now that 2009 H1N1 has become seasonal.
The major limitation of our study is that the lower sensitivity than
earlier published results (Ward et al., 2004) may be related to RNA
degradation while stored at−80 °C and, possibly, to the extra freeze–
thaw step that was introduced in this retrospective analysis of the kit.
Another (common) limitation is the lack of a true gold standard,
resulting in uncertainty regarding which samples are true positive
and true negative among those with discrepant results, and limiting
the applicability of found sensitivity and speciﬁcity values.
In conclusion, the Roche detection kit has a reasonable sensitivity
and a very good speciﬁcity (N95%). Sensitivity loss may have beencaused by storage and an extra freeze–thaw step. Some discrepan-
cies between Roche and CDC PCR most likely indicate that there is
not a true gold standard, rather than a speciﬁcity problem of the
Roche PCR. The Roche kit detects inﬂuenza virus A and subtypes
2009 H1N1 virus, but not other inﬂuenza A subtypes and does not
detect inﬂuenza B viruses. Therefore, a commercial PCR kit that has
primers/probes to detect and subtype all circulating inﬂuenza
viruses is more useful, now that it has become clear that 2009
H1N1 is ‘just a seasonal virus’.Acknowledgments
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